Borderline Personality DisorderMOTRNCT01896024
Effects of Motive-Oriented Therapeutic Relationship in the Early-Phase Treatment of Borderline Personality Disorder
A study testing Psychiatric Management and Motive-oriented therapeutic relationship/Plan Analysis in people with Borderline Personality Disorder, run by University of Lausanne Hospitals at 1 site in Switzerland.
Trial summary
The present research aims at examining the effectiveness of a specific set of therapist relational interventions and attitudes, called the Motive-Oriented Therapeutic Relationship (MOTR), based on Plan Analysis (Caspar, 2007) in the early-phase treatment of patients diagnosed with Borderline Personality Disorder. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Borderline Personality Disorder
- What is being tested?
- Psychiatric Management and Motive-oriented therapeutic relationship/Plan Analysis
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 85 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jun 2010to Apr 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- DSM-IV Borderline Personality Disorder;
- between 18 and 65 yrs of age
Who cannot join
- DSM-IV psychotic disorders,
- mental retardation,
- substance abuse in the forefront
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Department of Psychiatry-CHUV, University of Lausanne
Lausanne, Canton of Vaud, 1004
About this study
The present research aims at examining the effectiveness of a specific set of therapist relational interventions and attitudes, called the Motive-Oriented Therapeutic Relationship (MOTR), based on Plan Analysis (Caspar, 2007) in the early-phase treatment of patients diagnosed with Borderline Personality Disorder.
The investigators intend to include N = 80 outpatients diagnosed with Borderline Personality Disorder, consulting at the Outpatient Personality Disorder Program of the Karl Jaspers Clinical Unit, in collaboration with the Institute of Psychotherapy, at the Department of Psychiatry-CHUV, University of Lausanne and in collaboration with the University of Berne, Switzerland. Patients are assigned by chance to two treatment conditions 1) Control condition (General Psychiatric Management; Gunderson \& Links, 2008) and 2) MOTR-condition. The investigators hypothesize better results in the MOTR-condition, as compared to the control condition in terms of symptom reduction pre-post.
The conduct of the study represents a significant contribution to the understanding and enhancement of relationship aspects in the treatment of patients diagnosed with Borderline Personality Disorder which may be of potential benefit for these patients.
- Conditions
- Borderline Personality Disorder
- Being tested
- Psychiatric Management, Motive-oriented therapeutic relationship/Plan Analysis
- Medical subject headings
- Borderline Personality Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Psychiatric ManagementBehavioural
Motive-oriented therapeutic relationship/Plan AnalysisBehavioural
| Study group | Role | What they receive |
|---|---|---|
| General Psychiatric Management (GPM; Gunderson & Links, 2008) | Active comparator | psychodynamic-psychiatric treatment for borderline personality disorder Receives: Behavioral: Psychiatric Management |
| GPM plus Motive-Oriented Therapeutic Relationship | Experimental | use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM Receives: Behavioral: Psychiatric Management; Behavioral: Motive-oriented therapeutic relationship/Plan Analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Outcome Questionnaire -45.2 (Lambert et al., 2004)
pre- post- intervention in a randomized controlle trial; measure of symptom reduction over 3 months
Measured: 3 months
Secondary outcomes (1)
Inventory of Interpersonal Problems (Horowitz et al., 1988)
Measure of interpersonal problems after 3 months of therapy
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2013 (estimated)
- Study startJun 2010
- Primary completionMay 2013
- Study completionApr 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Borderline Personality DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 85 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Lausanne Hospitals
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ueli Kramer, University of Lausanne Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01896024
- Sponsor's protocol ID
- SNSF 100014-134562
- Acronym
- MOTR
- Status last verified
- Dec 2014
- First submitted
- 5 Jul 2013
- Last updated
- 2 Dec 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Kramer U, Berger T, Kolly S, Marquet P, Preisig M, de Roten Y, Despland JN, Caspar F. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. J Nerv Ment Dis. 2011 Apr;199(4):244-50. doi: 10.1097/NMD.0b013e3182125d19.
PubMed 21451348Kramer U, Kolly S, Berthoud L, Keller S, Preisig M, Caspar F, Berger T, de Roten Y, Marquet P, Despland JN. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom. 2014;83(3):176-86. doi: 10.1159/000358528. Epub 2014 Apr 17.
PubMed 24752034Kramer U, Fluckiger C, Kolly S, Caspar F, Marquet P, Despland JN, de Roten Y. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychother Psychosom. 2014;83(6):386-7. doi: 10.1159/000365400. Epub 2014 Oct 16. No abstract available.
PubMed 25324025Sallin L, Geissbuehler I, Grandjean L, Beuchat H, Martin-Soelch C, Pascual-Leone A, Kramer U. Self-Contempt, the Working Alliance and Outcome in Treatments for Borderline Personality Disorder: An Exploratory Study. Psychother Res. 2021 Jul;31(6):765-777. doi: 10.1080/10503307.2020.1849848. Epub 2020 Nov 30.
PubMed 33256540Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongerslev MT, Mattivi JT, Jorgensen MS, Faltinsen E, Todorovac A, Sales CP, Callesen HE, Lieb K, Simonsen E. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020 May 4;5(5):CD012955. doi: 10.1002/14651858.CD012955.pub2.
PubMed 32368793Penzenstadler L, Kolly S, Rothen S, Khazaal Y, Kramer U. Effects of substance use disorder on treatment process and outcome in a ten-session psychiatric treatment for borderline personality disorder. Subst Abuse Treat Prev Policy. 2018 Feb 26;13(1):10. doi: 10.1186/s13011-018-0145-6.
PubMed 29482597
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Motive-Oriented Therapeutic Relationship in the Early-Phase Treatment of Borderline Personality Disorder
- ClinicalTrials.gov ID
- NCT01896024
- Acronym / sponsor ID
- MOTR / SNSF 100014-134562
- Conditions
- Borderline Personality Disorder
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 85 participants (actual)
- Lead sponsor
- University of Lausanne HospitalsUniversity, hospital or other
- Study start
- Jun 2010
- Primary completion
- May 2013 (actual)
- Study completion
- Apr 2014 (actual)
- First posted
- 11 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present research aims at examining the effectiveness of a specific set of therapist relational interventions and attitudes, called the Motive-Oriented Therapeutic Relationship (MOTR), based on Plan Analysis (Caspar, 2007) in the early-phase treatment of patients diagnosed with Borderline Personality Disorder.
The investigators intend to include N = 80 outpatients diagnosed with Borderline Personality Disorder, consulting at the Outpatient Personality Disorder Program of the Karl Jaspers Clinical Unit, in collaboration with the Institute of Psychotherapy, at the Department of Psychiatry-CHUV, University of Lausanne and in collaboration with the University of Berne, Switzerland. Patients are assigned by chance to two treatment conditions 1) Control condition (General Psychiatric Management; Gunderson \& Links, 2008) and 2) MOTR-condition. The investigators hypothesize better results in the MOTR-condition, as compared to the control condition in terms of symptom reduction pre-post.
The conduct of the study represents a significant contribution to the understanding and enhancement of relationship aspects in the treatment of patients diagnosed with Borderline Personality Disorder which may be of potential benefit for these patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| General Psychiatric Management (GPM; Gunderson & Links, 2008) | Active comparator | Behavioral: Psychiatric Managementpsychodynamic-psychiatric treatment for borderline personality disorder |
| GPM plus Motive-Oriented Therapeutic Relationship | Experimental | Behavioral: Psychiatric Management, Behavioral: Motive-oriented therapeutic relationship/Plan Analysisuse of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- DSM-IV Borderline Personality Disorder;
- between 18 and 65 yrs of age
Key exclusion criteria (3 listed)
- DSM-IV psychotic disorders,
- mental retardation,
- substance abuse in the forefront
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Psychiatric Management | Behavioural | GPM plus Motive-Oriented Therapeutic Relationship, General Psychiatric Management (GPM; Gunderson & Links, 2008) |
| Motive-oriented therapeutic relationship/Plan Analysis | Behavioural | GPM plus Motive-Oriented Therapeutic Relationship |
Primary outcome
Outcome Questionnaire -45.2 (Lambert et al., 2004)
Time frame: 3 months
pre- post- intervention in a randomized controlle trial; measure of symptom reduction over 3 months
1 secondary outcome
Inventory of Interpersonal Problems (Horowitz et al., 1988)
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2014.
- Results publication: PubMed 21451348Kramer U, Berger T, Kolly S, Marquet P, Preisig M, de Roten Y, Despland JN, Caspar F. Effects of motive-oriented therapeutic relationship in early-phase treatment of borderline personality disorder: a pilot study of a randomized trial. J Nerv Ment Dis. 2011 Apr;199(4):244-50. doi: 10.1097/NMD.0b013e3182125d19.
- Results publication: PubMed 24752034Kramer U, Kolly S, Berthoud L, Keller S, Preisig M, Caspar F, Berger T, de Roten Y, Marquet P, Despland JN. Effects of motive-oriented therapeutic relationship in a ten-session general psychiatric treatment of borderline personality disorder: a randomized controlled trial. Psychother Psychosom. 2014;83(3):176-86. doi: 10.1159/000358528. Epub 2014 Apr 17.
- Results publication: PubMed 25324025Kramer U, Fluckiger C, Kolly S, Caspar F, Marquet P, Despland JN, de Roten Y. Unpacking the effects of therapist responsiveness in borderline personality disorder: motive-oriented therapeutic relationship, patient in-session experience, and the therapeutic alliance. Psychother Psychosom. 2014;83(6):386-7. doi: 10.1159/000365400. Epub 2014 Oct 16. No abstract available.
- Derived from this study: PubMed 33256540Sallin L, Geissbuehler I, Grandjean L, Beuchat H, Martin-Soelch C, Pascual-Leone A, Kramer U. Self-Contempt, the Working Alliance and Outcome in Treatments for Borderline Personality Disorder: An Exploratory Study. Psychother Res. 2021 Jul;31(6):765-777. doi: 10.1080/10503307.2020.1849848. Epub 2020 Nov 30.
- Derived from this study: PubMed 32368793Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongerslev MT, Mattivi JT, Jorgensen MS, Faltinsen E, Todorovac A, Sales CP, Callesen HE, Lieb K, Simonsen E. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2020 May 4;5(5):CD012955. doi: 10.1002/14651858.CD012955.pub2.
- Derived from this study: PubMed 29482597Penzenstadler L, Kolly S, Rothen S, Khazaal Y, Kramer U. Effects of substance use disorder on treatment process and outcome in a ten-session psychiatric treatment for borderline personality disorder. Subst Abuse Treat Prev Policy. 2018 Feb 26;13(1):10. doi: 10.1186/s13011-018-0145-6.
Related trials for Borderline Personality Disorder
Recruiting
Repetitive Transcranial Magnetic Stimulation Versus Theta Burst Stimulation on Impulsivity, Emotional Dysregulation, and Non-Suicidal Self-Injury in Borderline Personality Disorder Patients
Borderline Personality Disorder (BPD)
Not yet recruitingPhase 2
Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder
Infusion of Ketamine in Severe Borderline Personality Disorder, Borderline Personality Disorder (BPD)
Recruiting
Combining Transcranial Magnetic Stimulation With Emotion Regulation Skills Training in Borderline Personality Disorder
Borderline Personality Disorder (BPD)
RecruitingPhase 2
MDMA in Borderline Personality Disorder
Borderline Personality Disorder
Active, not recruitingPhase 2
Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder
Borderline Personality Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Psychiatric Management and Motive-oriented therapeutic relationship/Plan Analysis in people with Borderline Personality Disorder, run by University of Lausanne Hospitals at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Outcome Questionnaire -45.2 (Lambert et al., 2004) (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01896024, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2014.